Premium
Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG‐141: A report from childrens cancer study group
Author(s) -
Miller Denis R.,
Leikin Sandford,
Albo Vincent,
Sather Harland,
Karon Myron,
Hammond Denman
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830315)51:6<1041::aid-cncr2820510612>3.0.co;2-g
Subject(s) - medicine , vincristine , prednisone , methotrexate , regimen , cyclophosphamide , gastroenterology , aclarubicin , lymphoblast , leukemia , acute lymphocytic leukemia , bone marrow , mercaptopurine , surgery , cytarabine , lymphoblastic leukemia , chemotherapy , biology , genetics , cell culture
From 1975 to 1978, 880 previously untreated patients with acute lymphoblastic leukemia (ALL) were entered on CCG‐141, a protocol designed to determine the importance of clinical predictors of remission‐induction, duration of complete continuous remission (CCR), and survival, and to determine the benefit of intensive therapy in patients with a poor prognosis. Patients with initial leukocyte count <20 × 10 9 /1 received prednisone (PDN), vincristine (VCR), L‐asparaginase (LASP), cranial irradiation and intrathecal (IT) methotrexate (MTX), and were maintained on 6‐mercaptopurine (6‐MP), MTX, and monthly PDN and VCR. Patients with initial leukocyte count >20 × 10 9 /1 were randomly assigned to this standard regimen or to a more intensive four‐drug regimen (PDN, VCR, LASP, and cyclophosphamide) and a maintenance program consisting of alternating cycles of PDN, VCR, 6‐MP, and MTX (POMP) and PDN, VCR, cytosine arabinoside, and Adriamycin (POCA). The overall rate of complete remission (CR) was 93%. Factors associated with a significantly lower rate of CR were: M 3 bone marrow (BM) on day 14, CNS leukemia at diagnosis, L 3 , morphology, less than 40% PAS‐positive lymphoblasts, low IgG, age >10 years, and L 2 morphology. The relapse rate in patients with an initial leukocyte count <20 × 10 9 /1 was significantly lower than in patients with an initial leukocyte count >20 × 10 9 /1. By multivariate analysis, adverse predictors of duration of CCR were leukocyte count >50 × 10 9 /1, Hb >10 g/dl, low IgM, massive splenomegaly, age <1 yr, M 3 BM on day 14 and male sex. More intensive maintenance therapy did not prolong the duration of CCR in patients with initial leukocyte count >20 × 10 9 /1. By life table analysis, 80% of patients with good prognostic factors remain in CCR at four years. In patients with poor prognostic factors, the CCR rate at four years is 43%. This study demonstrates the utility of clinical prognostic factors in identifying subsets of patients at low and high probability of treatment failure. Intensive induction and maintenance therapy as used in this protocol did not benefit the poor prognosis group.